Search

Module 4 - PRRT Treatments: Day Case or Overnight?

Module 4 - Setting up a new therapy unit PRRT Treatments: Day Case or Overnight?
Eleni Kalogianni

In this 9-minute masterclass, Ms Kalogianni gives a practical overview of the outpatient approach to PRRT at King’s College Hospital, London,...
Module 3 - PRRT Treatment Pathway

Module 3 - PRRT administration and set-up PRRT Treatment Pathway
Ivy Vito

In this 20-minute masterclass, Mrs Vito shares best practice from the Royal Free Hospital for ¹⁷⁷Lu-oxodotreotide treatment, focusing on the treatment...
Module 5 - Radiation Protection

Module 5 - Radiation protection Radiation Protection, Regulations, Risk Assessments and Contingency Plans
Richard Meades

In this 30-minute masterclass, Richard Meades explores the fundamental radioactive characteristics of lutetium-177,...
Module 2 - Current Evidence for PRRT

Current Evidence for PRRT In this 30-minute masterclass, Dr Navalkissoor shares his knowledge of the evidence supporting the use of 177Lu-oxodotreotide, the first approved PRRT for NETs, and the factors influencing patient selection for PRRT.
PRRT Masterclass 2021 - NETTER-1 update and case presentations Dr Alia Munir

Session 2 - PRRT in practice: Current evidence, patient selection, and challenges
NETTER-1 update and case presentations

Dr Alia Munir

Dr Alia Munir, Consultant Endocrinologist at Sheffield Teaching Hospitals NHS Foundation Trust ,...
Patient selection and challenges in PRRT

Patient selection and challenges in PRRT Dr Shaunak Navalkissoor speaks about patient selection for peptide receptor radionuclide therapy (PRRT), with a focus on molecular imaging, and describes the challenges associated with this process.
When to refer patients to PRRT centre

When to refer patients to PRRT centre Dr Mohid Khan describes the service model of NET care, information required for referral, patient preparation and selection, and more.
Identifying progression in NETs: clinical, biochemical and imaging markers

Identifying progression in NETs: clinical, biochemical and imaging markers Prof. Martyn Caplin reports on emerging methods for neuroendocrine tumour (NET) diagnosis, including the NETest and sheds light on available treatment options for...
PRRT Masterclass 2021 - PRRT: revisiting the Lutathera® ([177Lu]Lu-oxodotreotide) SmPC by Dr Gopinath Gnanasegaran

Session 2 - PRRT in practice: Current evidence, patient selection, and challenges
PRRT: revisiting the Lutathera® ([177Lu]Lu-oxodotreotide) SmPC

Dr Gopinath Gnanasegaran

Dr Gopinath Gnanasegaran, Consultant in Nuclear Medicine at the...
PRRT Masterclass 2021 - History of nuclear medicine imaging and therapy in NETs by Dr John Buscombe

Session 1: PRRT in GEP-NETs: Optimising the patient journey for improved patient outcomes History of nuclear medicine imaging and therapy in NETs
Dr John Buscombe

Dr John Buscombe, Locum Consultant Physician in Nuclear Medicine at Barts...

previous

page of 4

next

×

Pages

Ask Speakers

Medical Information Request